Nurix discovers drugs that harness the body’s natural process to control protein levels.
Nurix discovers drugs that harness the body’s natural process to control protein levels. Dysregulated or mutated proteins are at the core of nearly every human disease. Novel therapies that control protein levels provide an opportunity for a new therapeutic approach to alter the development and progression of a broad range of diseases.
Nurix discovers and develops small molecule drugs that control E3 ubiquitin ligases, the key enzymes responsible for protein breakdown in human cells. Our initial focus is on a unique modality that manipulates protein breakdown for new treatments of hematologic cancers, immune-mediated diseases and in applications in immuno-oncology.
In September 2015, Nurix entered into a major collaboration with Celgene for the discovery and development of next-generation therapies targeting E3 ubiquitin ligases in oncology, immunology, and inflammation.
Nurix was founded by a team of experts in E3 ubiquitin ligase regulation and structure. The Nurix management team has extensive experience in biopharmaceutical drug development and is building an innovative biotechnology company around these exciting approaches to create new medicines to improve the lives of patients. The company is funded by leading life science investors Third Rock Ventures and The Column Group, and is headquartered in San Francisco, California.